Perinatal outcomes associated with the use of glargine during pregnancy
- PMID: 18959615
- PMCID: PMC2613261
- DOI: 10.1111/j.1464-5491.2008.02485.x
Perinatal outcomes associated with the use of glargine during pregnancy
Abstract
Aims: Insulin glargine (IG), with its non-peaking action profile, might be useful in diabetic pregnancy. However, data on its safety are limited and its use during pregnancy is not recommended. This study focused on the effects of IG on perinatal outcome, particularly to estimate the rate of congenital anomalies and birthweight.
Methods: This retrospective study included women with pre-gestational diabetes who used IG before (at least 1 month) and during pregnancy. For all women we recorded data regarding maternal glycaemic control and pregnancy outcome. We also compared women treated with IG throughout pregnancy and women who stopped taking IG at an earlier stage.
Results: From 27 centres, 107 Type 1 diabetic pregnancies were identified. IG was started 10.3 +/- 6.9 months before conception and in 57.4% of cases was stopped during the first trimester; 42.6% of women continued using it until the end of pregnancy. There were six abortions (four spontaneous and two induced) and five newborns (4.9%) with congenital anomalies. Glycaemic control, birthweight and the prevalence of macrosomia and neonatal morbidity were similar in women who used IG for the full term compared with those who stopped IG earlier during pregnancy.
Conclusions: This study, although limited, suggests that IG is safe and effective; the rate of congenital malformations was within the range expected for diabetic pregnancies treated with more traditional forms of insulin. IG used throughout pregnancy did not seem to influence birthweight or increase adverse outcomes.
Similar articles
-
Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.Clin Ther. 2008 Aug;30(8):1476-84. doi: 10.1016/j.clinthera.2008.08.013. Clin Ther. 2008. PMID: 18803989
-
Use of insulin glargine during pregnancy: a case-control pilot study.BJOG. 2007 Apr;114(4):453-7. doi: 10.1111/j.1471-0528.2006.01216.x. Epub 2007 Jan 25. BJOG. 2007. PMID: 17261126
-
Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes.Diabetes Metab. 2010 Jun;36(3):209-12. doi: 10.1016/j.diabet.2009.11.008. Epub 2010 Feb 25. Diabetes Metab. 2010. PMID: 20188617
-
Safety of insulin analogs during pregnancy: a meta-analysis.Arch Gynecol Obstet. 2015 Oct;292(4):749-56. doi: 10.1007/s00404-015-3692-3. Epub 2015 Apr 9. Arch Gynecol Obstet. 2015. PMID: 25855052 Review.
-
Insulin glargine use during pregnancy.Endocr Pract. 2011 May-Jun;17(3):448-55. doi: 10.4158/EP11083.RA. Endocr Pract. 2011. PMID: 21613047 Review.
Cited by
-
Gestational diabetes mellitus: insulinic management.J Obstet Gynaecol India. 2014 Apr;64(2):82-90. doi: 10.1007/s13224-014-0525-4. Epub 2014 Mar 18. J Obstet Gynaecol India. 2014. PMID: 24757334 Free PMC article. Review.
-
Type 1 diabetes mellitus and pregnancy.Rev Obstet Gynecol. 2010 Summer;3(3):92-100. Rev Obstet Gynecol. 2010. PMID: 21364860 Free PMC article.
-
Management of gestational diabetes mellitus.Diabetes Metab Syndr Obes. 2009 Jun 17;2:73-82. doi: 10.2147/dmsott.s3407. Diabetes Metab Syndr Obes. 2009. PMID: 21437120 Free PMC article.
-
Maternal and neonatal outcomes with the use of long acting, compared to intermediate acting basal insulin (NPH) for managing diabetes during pregnancy: a systematic review and meta-analysis.Diabetol Metab Syndr. 2022 Oct 21;14(1):154. doi: 10.1186/s13098-022-00925-7. Diabetol Metab Syndr. 2022. PMID: 36271431 Free PMC article. Review.
-
Use of Insulin Lispro Protamine Suspension in Pregnancy.Adv Ther. 2015 Oct;32(10):888-905. doi: 10.1007/s12325-015-0244-y. Epub 2015 Oct 26. Adv Ther. 2015. PMID: 26499176 Free PMC article. Review.
References
-
- Owens DR, Zinnan B, Bolli GB. Insulin today and beyond. Lancet. 2001;358:739–746. - PubMed
-
- Manderson JG, Patterson CC, Hadden DR, Traub Al, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in Type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003;189:507–512. - PubMed
-
- Slieker LJ, Brooke GS, Di Marchi R, Flora D, Green LK, Hoffmann JA. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia. 1997;40:54–61. - PubMed
-
- Devlin JT, Hothershall L, Wilkis JL. Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabetes Care. 2002;25:1095–1096. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical